Jefferies Financial Group Raises Pediatrix Medical Group (NYSE:MD) Price Target to $18.00

Pediatrix Medical Group (NYSE:MD) had its target price raised by equities research analysts at Jefferies Financial Group from $14.00 to $18.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s target price points to a potential upside of 12.08% from the stock’s previous close.

Several other brokerages have also issued reports on MD. Truist Financial boosted their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Mizuho lifted their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday. UBS Group increased their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $16.06 on Tuesday. The company’s fifty day moving average is $11.89 and its two-hundred day moving average is $9.54. Pediatrix Medical Group has a 52-week low of $6.62 and a 52-week high of $16.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.38. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -5.25, a P/E/G ratio of 2.35 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same period in the previous year, the company posted $0.29 earnings per share. The company’s quarterly revenue was up .9% compared to the same quarter last year. Equities research analysts forecast that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insider Activity at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the transaction, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO C Marc Richards sold 17,438 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $10.08, for a total transaction of $175,775.04. Following the sale, the chief financial officer now directly owns 175,347 shares in the company, valued at $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,100 shares of company stock valued at $701,889 in the last three months. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several large investors have recently made changes to their positions in MD. Aristeia Capital L.L.C. bought a new stake in Pediatrix Medical Group during the 2nd quarter worth about $687,000. Vanguard Group Inc. lifted its holdings in Pediatrix Medical Group by 1.6% in the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after buying an additional 164,333 shares during the period. Boston Partners boosted its stake in Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after acquiring an additional 453,254 shares during the last quarter. Rubric Capital Management LP grew its holdings in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the period. Finally, ClariVest Asset Management LLC bought a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at $1,721,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.